Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IMVT 
Immunovant Inc (IMVT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/22/2025: IMVT (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $50.25
Year Target Price $50.25
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 131.26% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 05/22/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.75B USD | Price to earnings Ratio - | 1Y Target Price 43.38 |
Price to earnings Ratio - | 1Y Target Price 43.38 | ||
Volume (30-day avg) - | Beta 0.61 | 52 Weeks Range 12.72 - 34.47 | Updated Date 06/29/2025 |
52 Weeks Range 12.72 - 34.47 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.97% | Return on Equity (TTM) -62.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2037990375 | Price to Sales(TTM) - |
Enterprise Value 2037990375 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -14.12 | Shares Outstanding 170923008 | Shares Floating 63258673 |
Shares Outstanding 170923008 | Shares Floating 63258673 | ||
Percent Insiders 58.37 | Percent Institutions 55.83 |
Analyst Ratings
Rating 4.64 | Target Price 50.25 | Buy 3 | Strong Buy 10 |
Buy 3 | Strong Buy 10 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Immunovant Inc
Company Overview
History and Background
Immunovant, Inc. was founded in 2018 and focuses on developing therapies for autoimmune diseases. It aims to target FcRn (neonatal Fc receptor) to reduce levels of disease-causing antibodies.
Core Business Areas
- Autoimmune Disease Therapies: Immunovant focuses on the development and commercialization of novel therapies for autoimmune diseases. Their lead candidate is batoclimab, an anti-FcRn antibody.
Leadership and Structure
The leadership team includes Pete Stein as CEO. The organizational structure reflects a typical biotech company focusing on research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Batoclimab: Batoclimab is Immunovant's lead product candidate, a fully human anti-FcRn monoclonal antibody being developed for the treatment of multiple autoimmune diseases. Market share data is not yet available as the product is still in clinical trials. Competitors include Argenx (ARGX) with Vyvgart, and UCB with Rystiggo, which are both FcRn inhibitors.
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is large and growing, with significant unmet needs. FcRn inhibitors represent a promising new class of drugs for treating a variety of autoimmune conditions.
Positioning
Immunovant is positioning itself as a key player in the FcRn inhibitor space, targeting a range of autoimmune diseases. Their competitive advantage lies in their specific antibody and clinical development strategy.
Total Addressable Market (TAM)
The TAM for autoimmune disease treatments is estimated to be in the tens of billions of dollars annually. Immunovant aims to capture a significant share of this market by developing and commercializing batoclimab.
Upturn SWOT Analysis
Strengths
- Promising lead product candidate (batoclimab)
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Reliance on a single lead product candidate
- Clinical trial risks
- No approved products, pre-revenue company
Opportunities
- Successful clinical trial results
- Expansion into new autoimmune indications
- Partnerships with larger pharmaceutical companies
Threats
- Competition from established players (Argenx, UCB)
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ARGX
- UCB
Competitive Landscape
Immunovant is a newer player in the FcRn inhibitor market compared to Argenx and UCB. Its success depends on demonstrating comparable or superior efficacy and safety with batoclimab.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is characterized by advancements in its clinical trial pipeline.
Future Projections: Future growth is dependent on the successful development and commercialization of batoclimab. Analyst estimates will vary based on clinical trial progress and market conditions.
Recent Initiatives: Recent initiatives include initiating and advancing clinical trials for batoclimab in multiple autoimmune indications.
Summary
Immunovant is a clinical-stage biotech company with a promising lead candidate, batoclimab, targeting autoimmune diseases. While it faces competition from established players and the inherent risks of drug development, successful clinical trials could significantly enhance its value. The company needs to ensure it has sufficient funding for R&D and navigates regulatory hurdles effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Immunovant Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and represents a snapshot in time. Investment decisions should be based on thorough due diligence and professional financial advice. Market share data are estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunovant Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-06-21 | CEO & Director Dr. Eric Venker M.D., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 362 | Website https://immunovant.com |
Full time employees 362 | Website https://immunovant.com | ||
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.